Patients
Clinical trials
We are currently conducting a clinical trial evaluating RPT1G in patients with two types of blood cancers: relapsed/refractory AML and higher-risk MDS.
If you have any questions or would like to learn more about participating, please contact [email protected]
RPT1G-1002: A Phase 1 Multi-Center, Open-Label Study of RPT1G in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
This study is designed to determine what dose of RPT1G is best for cancer patients, understand how it works in the body, and see whether it can help treat relapsed/refractory AML or higher-risk AML.
NCT# 07107126
Patient Clinical Trial Resources
FAQ
Lorem ipsum dolor?
Phasellus non mi id massa luctus commodo. Ut eget nibh a nisl semper vehicula.
Lorem ipsum dolor?
Phasellus non mi id massa luctus commodo. Ut eget nibh a nisl semper vehicula.
Lorem ipsum dolor?
Phasellus non mi id massa luctus commodo. Ut eget nibh a nisl semper vehicula.
Lorem ipsum dolor?
Phasellus non mi id massa luctus commodo. Ut eget nibh a nisl semper vehicula.
Lorem ipsum dolor?
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam eu sem erat. Vestibulum pulvinar eu dui a hendrerit. Pellentesque imperdiet faucibus massa nec facilisis. Phasellus non mi id massa luctus commodo. Ut eget nibh a nisl semper vehicula.
